Chemists’ technique reveals whether antibodies neutralize SARS-CoV-2

GlycoSeLect provided the MIT team with Recombinant Prokaryotic Lectins. These RPLs assisted Prof. Laura Kiessling (MIT Novartis Professor of Chemistry and founding Editor of ACS Chemical Biology) and her team with their research and findings. We are grateful for the opportunity and proud to be associated with a prestigious institution.

“It was a pleasure working with the MIT team and support them with their research. Thank you to our former colleagues, Dr. Subhra Pradhan and Maria Tejero for their expertise and enthusiasm,” – Robert Dunne, CEO of GlycoSeLect.

Full publication available in the GlycoSeLect Research Paper download section.

About GlycoSelect Ltd

GlycoSeLect Ltd develops innovative technologies for the analysis, characterisation and purification of biopharmaceuticals. These next-generation products are highly specific for glycan structures improving product development and improving the cost-efficiency of their manufacturing. GlycoSeLect specialises in the development of proteins based on recombinant prokaryotic lectins RPLs. Our RPL products advance efficient detection, analysis and selective isolation of glycosylated pharmaceutical products. GlycoSeLect’s family of RPLs products are associated with market-leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness in process development.

More Stories